Workshops & seminars

Design of Biologically Active Ruthenium Complexes and Development of Novel Strategies for their Delivery
Dr. Annie Castonguay (Institut National de la Recherche Scientifique)

Friday, February 8, 2019
3 p.m. – 4:30 p.m.

Dr. Annie Castonguay


This event is free



Richard J. Renaud Science Complex
7141 Sherbrooke W.
Room SP-157



ABSTRACT:  Our research program aims at creating innovative metal-based therapeutics that could potentially overcome problems associated with existing chemotherapies. This presentation will focus on different aspects of a promising class of anticancer metallic compounds, notably Ru(II) and Ru(III) organometallic/coordination complexes, and the influence of various structural transformations on their anticancer properties. We are particularly interested in the design of anticancer ruthenium complexes that include biologically active ligands in their structure, leading to drug candidates that display a considerable activity against cancer cells via multiple modes of action, simultaneously. We also aim at developing novel strategies for the delivery of ruthenium complexes that include moieties with the unique ability to undergo reversible cycloaddition reactions with cell-penetrating/targeting agents. This talk will provide an overview of our most recent findings.

BIO:  Annie has obtained a Ph.D. degree in organometallic chemistry from Université de Montréal, under the supervision of Prof. Davit Zargarian and Prof. André L. Beauchamp, where she worked on a project involving synthesis and catalysis studies of various pincer complexes of nickel and palladium formed via aliphatic C-H activation. On the completion of her thesis, she moved to Boston for a postdoctoral position at Tufts University, where she studied the kinetics of fast reactions involving complexes of molybdenum, with Prof. Elena Rybak-Akimova in collaboration with the labs of Prof. Christopher Cummins from MIT and Prof. Carl Hoff from U. Miami. To further her experience in organic synthesis, she accepted a postdoctoral position at McGill University where she worked with Prof. Ashok Kakkar and Prof. Theo van de Ven in collaboration with the Finnish company Kemira on the preparation and the functionalization of macromolecules of interest to industry. She completed her postdoctoral training with Prof. Dusica Maysinger (Pharmacology and Therapeutics) at McGill University, where she worked at the development of novel organometallic therapeutics and nanosensors for biological applications. She joined the Institut national de la recherche scientifique (INRS-Institut Armand-Frappier) in 2014, where she currently holds an assistant professor position.


Dr. Castonguay is the guest of Dr. Xavier Ottenwaelder.

Back to top

© Concordia University